Sponsors
We thank the following companies for their generous support of the 57th OOG Meeting 2023 in Berlin, Germany:
|
Aura Biosciences |
|
Eckert & Ziegler BEBIG GmbH |
|
Roche Pharma AG |
|
Heidelberg Engineering GmbH |
|
Immunocore Ireland Ltd |
|
Bayer Vital GmbH |
|
Delcath Systems Limited |
|
Optos GmbH |
|
RaySearch Laboratories AB |
|
Novartis Pharma GmbH |
|
Théa Pharma GmbH |
|
Ursapharm Arzneimittel GmbH |
Preface
Dear OOG members and guests,
It is a great pleasure to present to you on behalf of the
organizers and the OOG board the program of the 57th
OOG Meeting 13th to 16th April.
We are looking forward to welcoming you in Berlin.
More than 75 presentations are scheduled either as full presentations (8 min. + 2 min. discussion), or new to the OOG meetings, Rapid fire presentations (2 min. + 1 min. discussion).
There will be a YIN session to start with on Thursday afternoon and we have a total of eleven invited speakers all across the program.
The meeting includes multiple lunches, dinners and social activities for optimal social interaction.
We hope to meet you soon in Berlin
Robert M. Verdijk
(Rotterdam/NL)
Alexandre Moulin
(Lausanne/CH)
Antonia M. Joussen
(Berlin/D)
General information
Scientific programme and further information
Prof. Dr. Antonia M. Joussen
Charité - Universitätsmedizin Berlin
Campus Benjamin Franklin (CBF), Department of Ophthalmology
Hindenburgdamm 30, 12200 Berlin
Charité - Universitätsmedizin Berlin
Campus Virchow-Klinikum (CVK), Department of Ophthalmology
Augustenburger Platz 1, 13353 Berlin
E-Mail: Anke.Walz@charite.de
Organisation
Congress-Organisation Gerling GmbH
Werftstraße 23, 40549 Düsseldorf, Germany
Phone +49 (0) 2 11 / 59 22 44
Fax +49 (0) 2 11 / 59 35 60
E-Mail info@congresse.de
Homepage www.congresse.de
Venue
Kaiserin-Friedrich-Stiftung
Robert-Koch-Platz 7, 10115 Berlin
www.kaiserin-friedrich-stiftung.com
Lecture hall
Auditorium
Official Language
English
Date
Thursday, April 13th, 2023, 13:00h - 19:00h
Friday, April 14th, 2023, 09:00h - 18:00h
Saturday, April 15th, 2023, 10:00h - 17:00h
Sunday, April 16th, 2023, guided tours
Opening hours congress office
Thursday, April 13th, 2023, 11:00h - 12:00h
Friday, April 14th, 2023, 08:00h - 18:00h
Saturday, April 15th, 2023, 08:30h - 17:00h
Sunday, April 16th, 2023, closed
Opening hours industrial exhibition
Friday, April 14th, 2023, 09:00h - 16:30h
Saturday, April 15th, 2023, 09:30h - 16:00h
Online Registration
Attendance fee
| Registration | until 1st April, 2023 | from 2nd April, 2023 |
|---|---|---|
| OOG Member | 250€ | 280€ |
| OOG non-ember | 300€ | 330€ |
| accompanying person | 100€ | 100€ |
The attendance fee covers the costs for coffee breaks, lunches and the social program.
Incl. VAT and excl. foreign transfer fees
Payment
by bank transfer (bank details are quoted on your confirmation and invoice. Please do not transfer money without noting your invoice number), PayPal or by credit card: VISA, AMERICAN EXPRESS, MASTERCARD
Important notes for participants
If you register late or on-site we cannot guarantee for lunch and
participation in the social program. |
Certificate of attendance / CME-Credits
The Symposium is registered at the Ärztekammer Berlin providing CME-credits for the German Continuing Medical Education System. Please bring your Barcode Labels and we will register you for CME-point documentation.
An equivalent Certificate of Attendance will be sent to you after the meeting by e-mail.
Information for speakers
Presentations
Duration, please see scientific program
Projection
Microsoft PowerPoint presentation
You are asked to preferably upload your presentation prior to
the meeting. The link will be sent to all speakers. Otherwise
you may bring a flash drive or own notebook.
Scientific program
Thursday, 13th April, 2023
| 11:00h - 12:00h |
Registration at Kaiserin Friedrich Stiftung |
| 12:00h |
Departure of the bus to Helmholtz Zentrum for Proton beam therapy |
| 12:45h - 13:00h |
small lunch provided |
| 13:00h |
Welcome |
| 13:10h |
Welcome YIN meeting |
| 13:20h |
Welcome |
| 13:30h - 14:40h |
Physics in Ocular Oncology (invited speakers)
Chairs: |
| 13:30h |
Advances in MRI of intra-ocular lesions |
| 13:50h |
Radiotherapy of intraocular tumors: present and future |
| 14:10h |
Ocular proton therapy worldwide results of the
PTCOG OPTIC questionnaire |
| 14:30h - 15:00h |
Experimental approaches
Chair: |
| 14:30h |
Organoids in Uveal melanoma research |
| 14:45h |
Comprehensive profiling benefits |
| 15:00h |
Break |
| 15:30h - 16:50h |
Presentations Imaging and Irradiation submitted abstracts
Chairs: |
| 15:30h |
Quantitative analysis of perfusion-weighted magnetic
resonance imaging in uveal melanoma |
| 15:40h |
Advantages of 3-D image-based versus conventional modelbased treatment planning in ocular proton therapy |
| 15:50h |
A-OCT in early recognition of radiation retinopathy -
a pilot study |
| 16:00h |
Radiation Maculopathy: |
| 16:10h |
Baseline MRI screening for bilateral retinoblastoma patients |
| 16:20h |
Advantages of Helium Ion beams in particle therapy of ocular tumors |
| 16:30h |
Status and Perspectives for the Treatment of Intra Ocular
Tumors with Protons and Helium Ions –
enabling ocular FLASH particle therapy |
| 16:40h |
From mice to man: in vivo analysis of retinal function in
animal models for retinal disease and its translational value |
| 16:50h - 20:00h |
Snacks and tour of the proton therapy facility |
| 20:30h |
Bus back to Berlin |
Friday, 14th April, 2023
| 09:00h - 10:00h |
Uveal melanoma Genetics (invited speakers)
Chair: |
| 09:00h |
Which are the important players in genetics? |
| 09:20h |
Is there progress in malignancy form small uveal melanoma
to large melanoma to metastasis? |
| 09:40h |
Genetics of ocular melanoma and non-malignant lesions |
| 10:00h - 11:00h |
Uveal melanoma presentations 1st round (submitted abstracts)
Chairs: |
| 10:00h |
Validation of AJCC staging for metastatic disease in a Danish cohort of patients with metastases from posterior uveal melanoma |
| 10:10h |
Iris melanoma outcomes based on The Cancer Genome Atlas
(TCGA) classification in 78 consecutive patients |
| 10:20h |
Uveal Melanoma App – current expert knowledge in digital form |
| 10:30h |
Survival of uveal melanoma patients with peritoneal
metastases: a retrospective single-center analysis |
| 10:40h |
The extraocular extension of the uveal melanoma |
| 10:50h |
Large optic disc melanocytoma: |
| 11:00h - 11:30h |
Break & Industrial Exhibition |
| 11:30h - 12:40h |
Uveal melanoma presentations 2nd round (submitted abstracts)
Chairs: |
| 11:30h |
Interdependence of molecular lesions that drive Uveal
Melanoma metastasis |
| 11:40h |
Atypical outcomes from uveal melanoma tumors with Class
1A, 1B, and 2 gene expression profiles |
| 11:50h |
Hyperglycemia-induced missegregation of chromosome-3
in the uveal melanoma cells |
| 12:00h |
Detection of ctDNA in vitreous body and aqueous humor of
uveal melanoma patients |
| 12:10h |
Application of multi-domain genomic data integration
for Uveal and Skin Melanoma |
| 12:30h |
Whole genome, methylation and transcriptome sequencing
of primary Uveal melanoma |
| 12:40h - 13:00h |
Uveal melanoma Metastasis - Prevention
Chair: |
| 12:40h |
System Medicine in Choroidal melanoma |
| 13:00h - 14:00h |
Lunch & Industrial Exhibition |
| 14:00h - 15:00h |
Collaborative initiatives - open discussion
Chairs: Request to all OOG members to mail collaborative proposals to the secretary: r.verdijk@erasmusmc.nl |
| 15:00h - 16:00h |
Uveal melanoma presentations 3rd round (submitted abstracts)
Chairs: |
| 15:00h |
A novel integrated concept to treat large intraocular tumors |
| 15:10h |
Iodine -125 Plaque Radiotherapy for Choroidal Melanoma.
Treatment Results, treatment related complications, Ocular
and Systemic Prognosis |
| 15:20h |
Deep-notch Episcleral Iodine-125 plaque for the treatment
of juxtapapillary melanoma |
| 15:30h |
Melanoma Recurrence or Something Else? |
| 15:40h |
Ruthenium brachytherapy for iridocilliary melanoma |
| 15:50h |
Uveal melanoma treatment with active scanning beam
protontherapy: the CNAO/INT experience |
| 16:00h - 16:30h |
Break & Industrial Exhibition |
| 16:30h - 18:00h |
Uveal melanoma presentations 4th round (submitted abstracts)
Chairs: |
| 16:30h |
Endoresection of choroidal melanoma after proton beam
irradiation: a retrospective interventional case series |
| 16:40h |
Review of 166 patients with iris melanoma treated proton
beam therapy |
| 16:50h |
Robotic CyberKnife Radiosurgery for the Treatment of Uveal
Melanoma |
| 17:00h |
A Phase 2 Trial of Belzupacap Sarotalocan (Bel-sar), a Firstin-Class Targeted Therapy for Choroidal Melanoma, via
Suprachoroidal Administration |
| 17:10h |
How to make strawberry ice cream: |
| 17:20h |
Detection of Circulating Tumor Cells in Small Choroidal
Melanocytic Lesions |
| 17:30h |
Identifying Uveal Melanoma Biomarkers from Patient
Extracellular Vesicles and the Pharmacological Action of
1,4 Dihydroxy Quininib |
| 17:40h |
Ergolide Mediates Anti-Cancer Effects on Metastatic Uveal Melanoma Cells and Modulates their Extracellular Vesicle Proteome |
| 18:00h |
departure on foot for Ship cruise |
| 19:15h |
Ship cruise with Dinner |
Saturday, 15th April, 2023
| 09:00h - 10:00h |
OOG Business Meeting
Chairs: |
| 10:00h - 10:20h |
Orbit Anterior Segment Tumors (invited speakers)
Chair: |
| 10:00h |
Different surgical approaches to the orbit are currently in
clinical use. There is limited clinical data on comparison of the
different options |
| 10:20h - 12:10h |
Orbit and ocular adnexa ((submitted abstracts)
Chairs: |
| 10:20h |
Global Trends in Incidence of Ocular Melanoma
and Iris Color Prevalence |
| 10:30h |
ATRX loss in (pre-) malignant melanocytic lesions
of the conjunctiva |
| 10:40h |
Treatment of Conjunctival Palpebral Tumors Using
Ruthenium Plaque Brachytherapy |
| 10:50h |
Malignant tumors of the eyelid and the eye surface: |
| 11:00h |
Epidemiological characteristics and clinical outcome of
facial Merkel cell carcinoma |
| 11:10h |
Post-operative Interventional Radiotherapy (Brachytherapy)
in advanced eye and eyelid tumors as alternative treatment
to invasive surgery |
| 11:20h |
The characteristics of childhood ocular and orbital
malignancies in the USA, 1996-2018 |
| 11:30h |
Novel characteristics of Orbital Solitary Fibrous Tumour: |
| 11:40h |
Two cases of intra-ocular undifferentiated pleomorphic sarcoma |
| 11:50h |
Ocular Oncology - Problems and Solutions in Animals |
| 12:10h - 13:00h |
Lunch & Industrial Exhibition |
| 13:00h - 13:20h |
Lymphoma (invited speaker)
Chair:
Speakers |
| 13:20h - 15:30h |
Retina (submitted abstracts)
Chairs: |
| 13:20h |
Molecular exploration of aqueous humor cfDNA in retinoblastoma |
| 13:30h |
Retinal giant cell astrocytoma: report of 2 cases |
| 13:40h |
Primary vitreoretinal lymphoma in the capital region of Denmark. |
| 13:50h |
Primary Vitreoretinal Lymphoma: |
| 14:00h |
Correlation of a preoperative priority list with the final diagnosis
of primary vitreoretinal lymphoma (PVRL) |
| 14:10h |
IL-10/IL-6 ratio in the diagnosis of intraocular lymphoma |
| 14:20h |
To analyse clinical outcome of Cyberknife SRT in a series of
patients with Choroidal hemangioma |
| 14:30h |
Outcome of combined cataract surgery and iris prosthesis
Implantation in patients with previous iris melanoma surgery |
| 14:40h |
Exudative retinal detachment in uveal melanomas treated with
interventional radiotherapy |
| 14:50h |
Outcome optimization after irradiation of ocular tumors |
| 15:00h |
Choroidal Vascular Changes Secondary to Ocular Irradiation
Because of Posterior UM |
| 15:10h |
In vivo preclinical model of radiation retinopathy |
| 15:20h - 16:00h |
Break & Industrial Exhibition |
| 16:00h - 17:00h |
Rapid fire session (2 min. presentation,1 min. discussion each)
Chairs:
Cyberknife Stereotactic Surgery for Vasoactive Proliferative Tumor of
the Retina
Prognostic significance of Bap1 protein expression in uveal melanoma
Choroidal biopsy success by technique:
The epidemiology of adults‘ ocular malignancies in Germany in a decade
The characteristics of adult ocular and orbital malignancies in the USA,
1996-2018
Presentation of a recurrent conjunctiva cyst, a case report and review of
literature
Orbital metastasis of a neuroendocrine tumor
Our Experience in The Management of Uveal Metastasis Based on Rare
Primary Tumor Origins: A Case Series
Everolimus in Tuberous Sclerosis Complex Patients with Retinal Hamartomas
Efficacy of Ultra-Low-Dose Radiotherapy in Association with Single-Agent
Rituximab Compared with Standard External Radiotherapy Alone in Low
Grade Orbital Lymphoma
Radiation-induced changes to the anterior segment of mice eye
Rise of an unexpected foe: |
| 17:30h |
Concert at the Kaiserin-Friedrich-Stiftung |
| 19:00h |
Dinner at Restaurant Habel am Reichstag |
Sunday, April 16th, 2023
On Sunday you are cordially invited to join one of the guided tours to the Reichstag, the New Museum with Nefertiti or the Jewish Museum (details see social program) to discover Berlin and deepen the meeting´s scientific exchange.
Authors
|
Dr. Luciano Accetta
Dr. Ahmed Samir Alfaar
Dr. Adriana Amaro
Martina Angi, MD, PhD
Dr. Jan-Willem Beenakker
Prof. Dr. Eckart Bertelmann
Dr. Alexander Böker
Prof. Dr. Norbert Bornfeld
Dr. Massimiliano Borselli
Dr. Erwin Brosens
Prof. Bertil Damato
Joris de Keersmaecker
Prof. Dr. Hakan Demirci
Prof. Dr. Andrea Denker
Dr. Ifeoma Chigozie Echieh
Dr. Maya Eiger-Moscovich
Carsten Faber, MD, PhD
Louis-Philippe Fermon
Dr. Paul Foerster
Prof. Shahar Frenkel
Dr. Johannes Gollrad |
Prof. Dr. Salvatore Grisanti
Michael Gutmann
Dr.rer.nat. Jens Heufelder
Dr. Tine Gadegaard Hindsö
Priv.-Doz. Dr. Martin Janz
Prof. Dr. Antonia M. Joussen
Prof. Dr. Ulrich Keilholz
Prof. Breandan Kennedy
Prof. Susan Kennedy
Prof. Jens Folke Kiilgaard
Dr. Emine Kilic
Dr. med. vet. Stefan Kindler
Lisa Klaassen
Dr. David S. Koca
Firas Kreidieh
Prof. Hatem Krema
Dr. Francesco Baldo Lanza
Dr. Claudia H. D. Le Guin
Prof. Dr. Serge Leyvraz
Dr. Denis Malaise |
Henning Manke
Dr. Alexandre Matet
Giulia Midena
Linda Mortimer
Priv.-Doz. Dr.
Weronika Mularska
Dr. Patrick Murtagh
Guy Negretti
Josephine Nguyen
Dr. Kristoffer Nissen
Priv.-Doz. Dr. Sebastian
Dr. Monica Mara Pagliara
Prof. Raffaele Parrozzani
Ass. Prof. Sapna Patel
Dr.rer.nat. Ulrich Pfeffer
Hibba Quhill
Dr. Philipp Rating
Dr. Francesco Reggiani
Stanislav Rosnev
Iwona Rospond-Kubiak , |
Dr. Clemens N. Rudolph
Ass. Prof. Gustavo Savino
Dr. Felix Schröder
Prof.Dr.rer.nat. Olaf Strauß
Dr. Valentina Tonelotto
Prof. Murat Tunc
Prof.Dr.rer.nat. Aysegül Tura
Jolique van Ipenburg
Dr. Natasha van Poppelen
Dr. Robert M. Verdijk
Dr. Vicktoria Vishnevskia-Dai
Dr.rer.nat. Andreas Weber
Dr. Susanne Wolf
Mike Wu
Dr. Marie-Laure Yaspo
Prof. Dr. Oliver Zeitz
Dr. Lynn S. zur Bonsen
Dr. Emilia Zwolinska |
Social program
Friday, April 14th, 2023 – start 19:15h
Ship cruise with Dinner
Starting at pier Friedrichstraße this tour will pass the Museumsinsel,
the Dome of Berlin and the historic Nikolaiviertel, the Reichstag, Berlin‘s government district, the new main station, Wedding, the Technical
Univerity Berlin, Chateau Bellevue (House of the German president),
the Federal Chancellery and plenty more interesting sites before finally
returning to Friedrichstraße.
The pier is in walking distance of the venue (appr. 1,3km).
Important: The ship will leave exactly at 19:15h due to a strict
schedule on Berlin´s waterways.
22:15h Return to pier Friedrichstraße
Saturday, April 15th, 2023 – 17:30h
17:30h Concert at the Kaiserin-Friedrich-Stiftung
Robert-Koch-Platz 7, 10115 Berlin
19:00h Dinner at Restaurant Habel am Reichstag
Luisenstraße 19, 10117 Berlin
Sunday, April 16th, 2023 – 10:00h-13:00h
Several guided tours are offered
Where German politic is made…
The Reichstag with guided tour
Meet the ancient pharaoh Nefertiti at the Neues Museum
https://www.museumsportal-berlin.de/de/museen/neues-museum/
The Jewish past and present in Germany
https://www.jmberlin.de/
Members of the Charité staff will accompany the groups to the guided tours.
Tours included, food & beverage not included.
Exhibitors
|
Aura Biosciences
Bayer Vital GmbH
Eckert & Ziegler BEBIG GmbH
Delcath Systems Limited
Heidelberg Engineering GmbH
Immunocore Ireland Ltd |
Novartis Pharma GmbH
Optos GmbH
RaySearch Laboratories AB
Roche Pharma AG |
Map
